Literature DB >> 30505957

Ischemic stroke as initial manifestation of systemic lupus erythematosus: A case report and review of the literature.

Stefanos Ioannidis1, Michael Mavridis1, Panayiotis D Mitsias1,2.   

Abstract

Stroke is a frequent occurrence among patients suffering from systemic lupus erythematosus (SLE), but it rarely occurs as the initial manifestation of the disease. We here present the case of a 37 year-old patient who developed an acute cerebellar ischemic stroke as initial event of SLE: elevated partial thromboplastin time and ESR, thrombocytopenia, anti-ds-DNA, anti-SSA, anti-JO-1, and the lupus anticoagulant were detected, and the diagnosis of SLE was established. In addition, we reviewed the literature in order to clarify the demographic, clinical, imaging and outcome characteristics of such a presentation, and found 10 similar cases. Most patients were young (age 31.7 ± 8.5 years) and women (8/11, 72.7%). Stroke most often affected the vertebrobasilar territory (7/11, 63.6%). The stroke mechanism was not clearly defined in these cases. Treatment with immunosuppression and anticoagulation was considered to be a reasonable choice for early secondary stroke prevention. The occurrence of ischemic stroke, primarily in the vertebrobasilar system among young patients, especially women, should always raise suspicion for underlying SLE, and prompt diagnostic investigations to confirm or exclude its presence.

Entities:  

Keywords:  Initial manifestation; Ischemic stroke; Stroke in young patient; Systemic lupus erythematosus

Year:  2018        PMID: 30505957      PMCID: PMC6251781          DOI: 10.1016/j.ensci.2018.11.001

Source DB:  PubMed          Journal:  eNeurologicalSci        ISSN: 2405-6502


Introduction

Systemic Lupus Erythematosus (SLE) is characterized by systemic inflammation, auto-antibodies and a relapsing-remitting course. SLE most often affects young women and is characterized by multi-system involvement. The central nervous system (CNS) is a frequent target of SLE, and its involvement leads to increased rates of morbidity and mortality [1]. Stroke events are frequent among patients suffering from SLE, affecting 3–20% of them, mainly in a young for stroke population, and usually within the first 5 years from diagnosis [[1], [2], [3], [4]]. The diagnosis of SLE is usually established before any stroke occurrence [5]. The risk of stroke is 8 times higher in SLE patients compared to the general population [3], and the risk for cardiovascular events is increased by 3% every year after diagnosis [1]. All these are responsible for 20–30% of deaths among SLE patients [1]. There are several potential mechanisms for cerebrovascular disorders in SLE, including hypercoagulable states, cardiogenic embolism, premature or accelerated atherosclerosis, and rarely vasculitis [3]. The clinical expression is also variable as SLE can cause transient cerebral ischemia (TIA), arterial ischemic stroke, intraparenchymal hemorrhage, subarachnoid hemorrhage, and cerebral venous thrombosis [1]. While cerebrovascular vascular events are common among patients with SLE, ischemic stroke as the first manifestation of the disease is rare and it can often be misdiagnosed. We here present the case of a young patient who developed an acute cerebellar ischemic stroke as initial manifestation of SLE, and review the literature in order to identify the demographic, clinical, imaging and outcome characteristics of such a presentation.

Methods

We present the case of a young patient who developed an acute cerebellar ischemic stroke and was subsequently diagnosed with systemic lupus erythematosus. In addition, we performed a literature search in the database PubMed using the terms “stroke AND lupus AND first manifestation”, “stroke AND lupus AND initial manifestation”, “vascular AND lupus AND initial manifestation”, and “vascular AND lupus AND first manifestation”. We reviewed all papers published in the English language and also their references in order to discover additional cases.

Results

Case report

A 37-year-old man presented to the emergency department complaining of acute onset dizziness, gait instability and vomiting. He was previously diagnosed with rheumatoid arthritis and hypothyroidism and received methotrexate occasionally. His father had dyslipidemia and coronary artery disease and his mother was diagnosed with SLE. General physical exam was unrevealing. Neurological examination revealed left hemiataxia and gait ataxia, with otherwise unremarkable findings. Admission NIHSS score was 2. Brain MRI demonstrated acute ischemic infarct in the territory of the left superior cerebellar artery (SCA) (Fig. 1).CT angiography revealed no large vessel occlusion, aneurysm or dissection. Admission laboratory tests revealed elevated partial thromboplastin time (56.2 s), mild elevation of ESR (26 mm/1st hour), thrombocytopenia (100.000/μL, down from 415,000/μL 7 days earlier), strongly positive anti-ds-DNA (409WHO/mL), anti-SSA (102.5 U/mL), anti-JO-1 (94.6 U/mL), and presence of lupus anticoagulant. Testing for protein-C, protein-S, anticardiolipin antibodies and anti-β2-GPI, CRP, rheumatoid factor, anti-Sm, anti-RNP, anti-SSB, anti-Scl, ANCA, AMA, ASMA, and direct Coombs revealed negative results. Transthoracic and transesophageal echocardiography were unremarkable.
Fig. 1

MRI DWI showing an acute ischemic lesion in the territory of the left superior cerebellar artery.

MRI DWI showing an acute ischemic lesion in the territory of the left superior cerebellar artery. During hospitalization, pancytopenia was observed. The diagnosis of SLE was established, according to the Systemic Lupus International Collaborating Clinics Classification (SLICC) criteria [6]. He was treated with high-dose intravenous corticosteroids, followed by oral prednisolone, and hydroxychloroquine, as well as IV heparin and subsequently acenocoumarol. The patient experienced gradual clinical and laboratory improvement. Follow up at three and twelve months revealed no neurological or functional abnormalities. The NIHSS score was 0.

Review of the literature

We identified 10 reported cases of stroke as initial event of SLE. These are summarized in Table 1, where we also include our patient.
Table 1

Summary of all reported patients with ischemic cerebrovascular event as initial manifestation of SLE.

Demographics relevant past historyInitial ischemic cerebrovascular eventNeuroimaging findingsLaboratory investigationsTreatment, follow-up & neurological outcome
29 y/o man [5]

Transient quadriparesis, unable to move jaw or speak

Transient vertebrobasilar ischemia after 5 months

Cerebral &left carotid angiography: normal

Positive antinuclear factor

Elevated DNA binding

Leukopenia, lymphopenia

C3 protein depression

Findings in renal biopsy

Normal ESR

Treatment not reported

Two TIAs after 16–19 months

Focal seizures after last episode

32 y/o woman, pregnant [5]

Transient left hemiparesis in immediate postpartum period

CT scan: normal

During pregnancy: Positive WR and VDRL, mild thrombocytopenia (30 × 10^9/l), positive antinuclear factor

Normal ESR

Three months postpartum: Severe thrombocytopenia (10 × 10^9/l), elevated DNA binding, positive anti-Sm antibody, C3 and C4 protein depression

Three months postpartum: Prednisone 60 mg per day, reducing to 10 mg per day.

Five or six TIAs within the next 12 months

Dipyridamole 400 mg per day was added.

No further events for the next 8 months

41 y/o woman, history of hepatitis and seronegative polyarhtritis [5]

Recurrent episodes of right hemiparesis [3] during 3 years

CT scan: cerebral atrophy, right temporo-parietal infarct

Normal ESR

Anti-Sm antibody absent

IgG elevation

Findings in renal biopsy

DNA binding elevation

Positive anti-ds-DNA

Positive LE cells

Treatment not reported

Persistent right facial weakness

Progressive dementia followed

46 y/o woman, history of paranoid psychosis [5]

Bilateral retinal artery occlusion

Epileptic seizures occurred 15 days after

Transient right hemiparesis 1 day later

Serial isotope scans: right frontal lobe infarct

CT scan at the age of 52 y/o: severe cerebral atrophy, infarcts in both temporal, left frontal and left parietal lobes.

Elevated ESR

Three months later: positive antinuclear factor, elevated DNA binding, positive WR, C3 and C4 protein depression, renal function impairment

Findings in renal biopsy

Treatment not reported

Focal and generalized seizures after 3 years, associated with prednisone-induced hyperglycemia and severe hypertension.

Aphasia, cognitive impairment, apraxic gait, bilateral extensor plantar response

16 y/o woman, history of skin red rash after sunlight exposure [4]

Multiple episodes of dizziness and headache

Acute dysarthria and quadriataxia.

MRI: multiple vertebrobasilar territory infarcts

Cerebral angiography: stenoses of left MCA, left vertebral, basilar and right PCA

MRI scan at the age of 19 y/o: no additional lesions

Leukocytosis

Positive ANA

Positive anti-ds-DNA

Positive direct Coombs Test

Positive lupus anticoagulant

Oral anticoagulation

IV cyclophosphamide monthly

6-months follow-up: ability to walk, ataxia, dysarthria

No further events for the next 3 years

26 y/o woman [4]

Acute headache, dizziness, dysarthria, quadriataxia.

MRI: multiple vertebrobasilar territory infarcts

Cerebral angiography: occlusion of bilateral vertebral arteries

Anemia

Leukocytosis

Elevated ESR

Weakly positive anti-ds-DNA

Positive ANA

Positive direct Coombs Test

Lupus anticoagulant absent

Antihypertensives, warfarin plus prednisolone

9-months follow-up: ability to stand and walk with assistance

24 y/o woman [12]

Acute headache, right hemiparesis and gait ataxia.

CT scan: normal

MRI: bilateral pontine infarcts

CTA: basilar artery stenosis

Weakly positive ANA

Positive anti-ds-DNA

C3 and C4 protein depression

Normal ESR

Heparin IV, initially

Further treatment not reported

Follow-up not reported

34 y/o man [12]

Acute headache, dizziness, right hemi-and gait ataxia, dysphagia and righthypesthesia

MRI: right cerebellar and pontine infarcts

CTA: right vertebral artery stenosis

Elevated ESR

Positive ANA

Positive anti-ds-DNA

Positive ASMA

C3 and C4 protein depression

Treatment not reported

Follow-up not reported

37 y/o woman [12]

Acute dizziness, right hemiparesis, horizontal nystagmus

Previously misdiagnosed as Multiple Sclerosis

MRI: multiple cerebellar and pontine ischemic lesions

CTA: left vertebral artery stenosis, hypoplastic right vertebral artery

LE cells absent

Normal ESR

Positive anti-ds-DNA

C3 and C4 protein depression

Treatment not reported

Follow-up not reported

27 y/o woman, 5th month of pregnancy [13]

Acute aphasia, right hemiparesis, right hypesthesia, right homonymous field defect

Catheter arteriogram: left internal carotid artery occlusion

CT: not applicable

Proteinuria

Elevated ESR

Positive LE cells

Treatment unknown

Follow-up unknown

37 y/o man, history of rheumatoid arthritis and hypothyroidism, mother's history of SLE

Acute dizziness, left hemiataxia and gait ataxia

MRI: acute ischemic lesion in the territory of left SCA

CTA: no large vessel occlusive disease

Elevated APTT

Thrombocytopenia, followed by pancytopenia

Positive anti-ds-DNA

Positive anti-SSA

Positive lupus anticoagulant

Elevated ESR

High-dose IV corticosteroids

Hydroxychloroquine

IV heparin, followed by acenocoumarol

No further events for the next 12 months

Anti-Sm antibody: anti-Smith antibody, ASMA: anti-smooth muscle antibody, APTT: activated partial thromboplastin time, CT: computerized tomography, CTA: CT angiography, ESR: erythrocyte sedimentation rate, IV: intravenous, FANA: fluorescent antinuclear antibody, LE cells: lupus erythematosus cell, MCA: middle cerebral artery, MRI: magnetic resonance imaging, PCA: posterior cerebral artery, TIA: transient ischemic attack, VDRL: venereal disease research laboratory, WR: Wassermann reaction.

Summary of all reported patients with ischemic cerebrovascular event as initial manifestation of SLE. Transient quadriparesis, unable to move jaw or speak Transient vertebrobasilar ischemia after 5 months Cerebral &left carotid angiography: normal Positive antinuclear factor Elevated DNA binding Leukopenia, lymphopenia C3 protein depression Findings in renal biopsy Normal ESR Treatment not reported Two TIAs after 16–19 months Focal seizures after last episode Transient left hemiparesis in immediate postpartum period CT scan: normal During pregnancy: Positive WR and VDRL, mild thrombocytopenia (30 × 10^9/l), positive antinuclear factor Normal ESR Three months postpartum: Severe thrombocytopenia (10 × 10^9/l), elevated DNA binding, positive anti-Sm antibody, C3 and C4 protein depression Three months postpartum: Prednisone 60 mg per day, reducing to 10 mg per day. Five or six TIAs within the next 12 months Dipyridamole 400 mg per day was added. No further events for the next 8 months Recurrent episodes of right hemiparesis [3] during 3 years CT scan: cerebral atrophy, right temporo-parietal infarct Normal ESR Anti-Sm antibody absent IgG elevation Findings in renal biopsy DNA binding elevation Positive anti-ds-DNA Positive LE cells Treatment not reported Persistent right facial weakness Progressive dementia followed Bilateral retinal artery occlusion Epileptic seizures occurred 15 days after Transient right hemiparesis 1 day later Serial isotope scans: right frontal lobe infarct CT scan at the age of 52 y/o: severe cerebral atrophy, infarcts in both temporal, left frontal and left parietal lobes. Elevated ESR Three months later: positive antinuclear factor, elevated DNA binding, positive WR, C3 and C4 protein depression, renal function impairment Findings in renal biopsy Treatment not reported Focal and generalized seizures after 3 years, associated with prednisone-induced hyperglycemia and severe hypertension. Aphasia, cognitive impairment, apraxic gait, bilateral extensor plantar response Multiple episodes of dizziness and headache Acute dysarthria and quadriataxia. MRI: multiple vertebrobasilar territory infarcts Cerebral angiography: stenoses of left MCA, left vertebral, basilar and right PCA MRI scan at the age of 19 y/o: no additional lesions Leukocytosis Positive ANA Positive anti-ds-DNA Positive direct Coombs Test Positive lupus anticoagulant Oral anticoagulation IV cyclophosphamide monthly 6-months follow-up: ability to walk, ataxia, dysarthria No further events for the next 3 years Acute headache, dizziness, dysarthria, quadriataxia. MRI: multiple vertebrobasilar territory infarcts Cerebral angiography: occlusion of bilateral vertebral arteries Anemia Leukocytosis Elevated ESR Weakly positive anti-ds-DNA Positive ANA Positive direct Coombs Test Lupus anticoagulant absent Antihypertensives, warfarin plus prednisolone 9-months follow-up: ability to stand and walk with assistance Acute headache, right hemiparesis and gait ataxia. CT scan: normal MRI: bilateral pontine infarcts CTA: basilar artery stenosis Weakly positive ANA Positive anti-ds-DNA C3 and C4 protein depression Normal ESR Heparin IV, initially Further treatment not reported Follow-up not reported Acute headache, dizziness, right hemi-and gait ataxia, dysphagia and righthypesthesia MRI: right cerebellar and pontine infarcts CTA: right vertebral artery stenosis Elevated ESR Positive ANA Positive anti-ds-DNA Positive ASMA C3 and C4 protein depression Treatment not reported Follow-up not reported Acute dizziness, right hemiparesis, horizontal nystagmus Previously misdiagnosed as Multiple Sclerosis MRI: multiple cerebellar and pontine ischemic lesions CTA: left vertebral artery stenosis, hypoplastic right vertebral artery LE cells absent Normal ESR Positive anti-ds-DNA C3 and C4 protein depression Treatment not reported Follow-up not reported Acute aphasia, right hemiparesis, right hypesthesia, right homonymous field defect Catheter arteriogram: left internal carotid artery occlusion CT: not applicable Proteinuria Elevated ESR Positive LE cells Treatment unknown Follow-up unknown Acute dizziness, left hemiataxia and gait ataxia MRI: acute ischemic lesion in the territory of left SCA CTA: no large vessel occlusive disease Elevated APTT Thrombocytopenia, followed by pancytopenia Positive anti-ds-DNA Positive anti-SSA Positive lupus anticoagulant Elevated ESR High-dose IV corticosteroids Hydroxychloroquine IV heparin, followed by acenocoumarol No further events for the next 12 months Anti-Sm antibody: anti-Smith antibody, ASMA: anti-smooth muscle antibody, APTT: activated partial thromboplastin time, CT: computerized tomography, CTA: CT angiography, ESR: erythrocyte sedimentation rate, IV: intravenous, FANA: fluorescent antinuclear antibody, LE cells: lupus erythematosus cell, MCA: middle cerebral artery, MRI: magnetic resonance imaging, PCA: posterior cerebral artery, TIA: transient ischemic attack, VDRL: venereal disease research laboratory, WR: Wassermann reaction. The mean age was 31.7 ± 8,5 years. Eight of 11 (72,7%) patients were women. In seven (63,6%) patients the affected arterial territory was the vertebrobasilar. CT or MRI scans results were reported in 9 patients and their findings were: multiple vertebrobasilar infarcts in more than one arterial territory (n = 6), single cerebral lobar infarct (n = 2), and no abnormal findings (n = 1). The most frequently affected area was the pons. Angiographic studies were reported in 8 patients and their findings were: stenosis of a single vessel of the vertebrobasilar system (n = 3), multiple stenosis involving both vertebrobasilar and carotid system (n = 1), bilateral occlusion of vertebral arteries (n = 1), left internal carotid artery occlusion (n = 1), and no abnormal findings (n = 2). The vertebral arteries were the most commonly affected arterial structure (4 of 8 studies). Reported laboratory findings were: positive anti-ds-DNA (n = 7), C3 and C4 protein depression (n = 6), elevated ESR (n = 5), positive antinuclear factor (n = 4), elevated DNA binding (n = 3), thrombocytopenia (n = 2), and lupus anticoagulant (n = 2). Treatment choices were reported in only 4 cases. In all, immunosuppressant therapy was used [IV prednisolone followed by oral prednisolone (n = 1), oral prednisolone (n = 2) and IV cyclophosphamide (n = 1)]. This was combined with IV anticoagulation followed by oral anticoagulation (n = 1), oral anticoagulation (n = 2) and dipyridamole (n = 1). Follow up data were scarcely documented. TIAs were reported in two cases (one with 2 episodes within 16–19 months, one with 5–6 episodes within 12 months). More permanent deficits were reported in two cases (in one case ataxia and dysarthria were reported at 6 months and in the other the patient was able to stand and walk with assistance at 9 months). Long-term cognitive impairment was reported in two cases. In our patient, no abnormal signs were found at the 3-month and 12-month follow-up, indicating fully recovery.

Discussion

Ischemic stroke as initial manifestation of SLE is an uncommon occurrence. It usually affects patients who are young, mostly women, and predominantly involves the vertebrobasilar territory. Treatment with immunosuppression and anticoagulation is a reasonable initial therapeutic approach. It is not unusual to encounter ischemic stroke in the course of SLE [3,5,7]. This may be in part related to SLE disease activity and in part to the operation of classic stroke risk factors, such as hypertension, dyslipidemia and others, which often accompany SLE and its treatment [8,9]. However, it is very rare to encounter stroke as the initial event of the disease. The paucity of reported cases attests to this fact. Stroke most often affects patients who are young, especially women. These demographic characteristics parallel those of the SLE population and are indirectly convincing that the stroke event was directly linked with SLE [10].Also, our patient was young, had predisposition to autoimmune diseases and no other obvious factors for vascular events were found. These facts convinced us that the underlying etiology was the presence of active SLE. It has been described that in SLE ischemic stroke is caused by several diverse mechanisms, including cardioembolism, large artery stenosis of either non-atherosclerotic or atherosclerotic etiology, arterial dissection, hypercoagulable states and rarely cerebral vasculitis [1,4]. Large vessel occlusion due to atherosclerosis is unusual in the early stages of the disease, where cardioembolism, hypercoagulable states and arterial dissection are the often diagnosed etiologies [11]. The majority of the patients (7 of 11), had ischemic infarcts in the distribution of the vertebrobasilar system, with the pons being the most frequently affected structure. In only three cases the pathogenic mechanism could be suspected (two cases compatible with dissection and one with inflammatory lesion), but eventually in none of them it was clearly identified. Nevertheless, all patients were found to have at least one auto-antibody, suggesting an underlying inflammatory or hypercoagulable state. Arterial stenoses were found in four cases, and arterial occlusions in two. In our case, the patient was investigated thoroughly, and, although cardiogenic embolism and vertebral artery dissection were the conditions that were initially considered in such a clinical scenario, the diagnostic investigations revealed no sign of either, and the event was attributed to a hypercoagulable state induced by highly active SLE. No other findings, such as large vessel atherosclerosis, cerebral aneurysm, vasculitis, systemic premature atherosclerosis, dyslipidemia, hypertension, or diabetes mellitus were discovered. The treatment choices were reported in only three of the cases we reviewed. In all of them, immunosuppressant therapy (either with oral prednisolone or IV cyclophosphamide) was used, in combination with oral anticoagulants or antiplatelet agent. For our patient we also elected to utilize immunosuppressant therapy (high dose IV corticosteroids, followed by oral prednisolone), hydroxycholoquine, and anticoagulation (IV heparin, followed by acenocoumarol). We feel that the combination of immunosuppressant and anticoagulation therapy is important for early secondary stroke prevention, because of the high activity of SLE and the high frequency of stroke recurrence after the initial vascular event. Follow up data were scarcely documented in the literature cases were reviewed, and at present the occurrence of ischemic stroke as first manifestation of SLE cannot be correlated with specific outcomes, especially the risk of a second stroke, myocardial infarction or death. Our patient showed no abnormal signs at 3-months and 12-months, indicating fully recovery.

Conclusions

The diagnosis of SLE is always a challenge due to the wide variety of its manifestations. The occurrence of ischemic stroke, primarily in the vertebrobasilar territory among young patients, especially women, should always raise suspicion for underlying SLE, and prompt diagnostic investigations to confirm or exclude its presence.
  13 in total

1.  CEREBROVASCULAR ACCIDENTS AS THE INITIAL MAJOR MANIFESTATION OF LUPUS ERYTHEMATOSUS.

Authors:  A SILVERSTEIN
Journal:  N Y State J Med       Date:  1963-10-15

2.  Stroke subtypes among young patients with systemic lupus erythematosus.

Authors:  Eswar Krishnan
Journal:  Am J Med       Date:  2005-12       Impact factor: 4.965

3.  Frequency, etiology, and prevention of stroke in patients with systemic lupus erythematosus.

Authors:  N Futrell; C Millikan
Journal:  Stroke       Date:  1989-05       Impact factor: 7.914

4.  Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.

Authors:  Michelle Petri; Ana-Maria Orbai; Graciela S Alarcón; Caroline Gordon; Joan T Merrill; Paul R Fortin; Ian N Bruce; David Isenberg; Daniel J Wallace; Ola Nived; Gunnar Sturfelt; Rosalind Ramsey-Goldman; Sang-Cheol Bae; John G Hanly; Jorge Sánchez-Guerrero; Ann Clarke; Cynthia Aranow; Susan Manzi; Murray Urowitz; Dafna Gladman; Kenneth Kalunian; Melissa Costner; Victoria P Werth; Asad Zoma; Sasha Bernatsky; Guillermo Ruiz-Irastorza; Munther A Khamashta; Soren Jacobsen; Jill P Buyon; Peter Maddison; Mary Anne Dooley; Ronald F van Vollenhoven; Ellen Ginzler; Thomas Stoll; Christine Peschken; Joseph L Jorizzo; Jeffrey P Callen; S Sam Lim; Barri J Fessler; Murat Inanc; Diane L Kamen; Anisur Rahman; Kristjan Steinsson; Andrew G Franks; Lisa Sigler; Suhail Hameed; Hong Fang; Ngoc Pham; Robin Brey; Michael H Weisman; Gerald McGwin; Laurence S Magder
Journal:  Arthritis Rheum       Date:  2012-08

Review 5.  Systemic lupus erythematosus: demographics, prognosis, and outcome.

Authors:  J H Klippel
Journal:  J Rheumatol Suppl       Date:  1997-05

Review 6.  Stroke in systemic lupus erythematosus and antiphospholipid syndrome: risk factors, clinical manifestations, neuroimaging, and treatment.

Authors:  L C D de Amorim; F M Maia; C E M Rodrigues
Journal:  Lupus       Date:  2017-04       Impact factor: 2.911

7.  Stroke as an early manifestation of systemic lupus erythematosus.

Authors:  L F Haas
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-06       Impact factor: 10.154

8.  Factors associated with arterial vascular events in PROFILE: a Multiethnic Lupus Cohort.

Authors:  A M Bertoli; L M Vilá; G S Alarcón; G McGwin; J C Edberg; M Petri; R Ramsey-Goldman; J D Reveille; R P Kimberly
Journal:  Lupus       Date:  2009-10       Impact factor: 2.911

Review 9.  Large cerebral vessel occlusive disease in systemic lupus erythematosus.

Authors:  P Mitsias; S R Levine
Journal:  Neurology       Date:  1994-03       Impact factor: 9.910

Review 10.  2013 update: Hopkins lupus cohort.

Authors:  Monthida Fangtham; Michelle Petri
Journal:  Curr Rheumatol Rep       Date:  2013-09       Impact factor: 4.592

View more
  5 in total

1.  Perfusion image guided mechanical thrombectomy combined with tirofiban successfully revascularize systemic lupus erythematosus related acute large vessel occlusion: A case report.

Authors:  Han Wang; Haitao Hu; Jing Xu; Cong Qian
Journal:  Medicine (Baltimore)       Date:  2021-05-07       Impact factor: 1.889

Review 2.  Neurological Complications in Patients with Systemic Lupus Erythematosus.

Authors:  Amir Shaban; Enrique C Leira
Journal:  Curr Neurol Neurosci Rep       Date:  2019-11-26       Impact factor: 6.030

3.  A Case Report of Pontine Infarction as an Initial Manifestation of Systemic Lupus Erythematosus: Diagnostic Clues from MRI and Digital Subtraction Angiography.

Authors:  Mi Sun Chung; Jun Soo Byun; Younghee Yim
Journal:  Taehan Yongsang Uihakhoe Chi       Date:  2021-08-27

4.  Characteristics of ischemic stroke and intracranial hemorrhage in patients with nephrotic syndrome.

Authors:  Wen-Yi Huang; Chun-Wei Chang; Chiung-Mei Chen; Kuan-Hsing Chen; Chien-Hung Chang; Hsiu-Chuan Wu; Kuo-Hsuan Chang
Journal:  BMC Nephrol       Date:  2021-06-05       Impact factor: 2.388

5.  Clinical study on the cerebral infarction accompanied with septic disseminated intravascular coagulation.

Authors:  Tetsuharu Kako; Fumika Azuma; Kazuya Nokura; Hideo Izawa
Journal:  Fujita Med J       Date:  2020-11-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.